文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

脑室内抗生素治疗脑膜炎与脑室炎:多中心回顾性队列研究的当前实践

Current Practices of Intraventricular Antibiotic Therapy in the Treatment of Meningitis and Ventriculitis: Results from a Multicenter Retrospective Cohort Study.
PubMed 文献 · Neurocrit Care · 2019-01-01
一句话结论多中心回顾性队列显示,脑室内抗生素(万古霉素52.4%、氨基糖苷类47.5%)使脑脊液培养转阴率达88.4%,总死亡率18.1%。

该多中心回顾性队列纳入2003年1月1日至2013年12月31日美国学术医学中心神经重症监护室收治的105例接受脑室内抗生素治疗的中枢神经系统感染患者,所有患者均同时接受全身抗菌治疗并至少接受一剂脑室内抗菌药物。脑室内万古霉素使用率52.4%,平均剂量12.2 mg/天,中位疗程5天;脑室内氨基糖苷类使用率47.5%,庆大霉素/妥布霉素平均剂量6.7 mg/天,中位疗程6天。总体死亡率18.1%,脑脊液培养转阴率88.4%,培养持续阳性或复发率9.5%。作者认为脑室内抗菌药物可带来高脑脊液转阴率,当前使用疗程通常不足一周,需前瞻性研究确定最佳人群及该给药途径的疗效与安全性。

要点

  • 105例接受脑室内抗生素的中枢神经系统感染患者中,脑脊液培养转阴率88.4%,培养持续阳性或复发率9.5%,总体死亡率18.1%。
  • 脑室内万古霉素使用率52.4%,平均剂量12.2 mg/天,中位疗程5天;所有患者均同时接受全身抗菌治疗。
  • 脑室内氨基糖苷类使用率47.5%(单用或联用万古霉素),庆大霉素/妥布霉素平均剂量6.7 mg/天,中位疗程6天。
  • 当前脑室内抗生素使用疗程通常不足一周(万古霉素中位5天、氨基糖苷类中位6天)。
  • 作者认为需前瞻性研究确定最佳患者人群及该给药途径的疗效与安全性。

适用人群与场景

  • 2003年1月1日至2013年12月31日美国参与中心重症监护室收治、接受脑室内抗生素治疗的中枢神经系统感染成人患者,共105例。

处置流程与药物剂量

  • 所有患者均接受全身抗菌治疗,并至少接受一剂脑室内抗菌药物。
  • 脑室内万古霉素用于52.4%的患者,平均剂量12.2 mg/天,中位疗程5天。
  • 脑室内氨基糖苷类用于47.5%的患者,单用或与脑室内万古霉素联用,庆大霉素/妥布霉素平均剂量6.7 mg/天,中位疗程6天。

研究设计与关键结果

  • 多中心回顾性队列研究,纳入美国参与中心2003年1月1日至2013年12月31日期间105例接受脑室内抗生素治疗的中枢神经系统感染患者。
  • 脑室内万古霉素使用率52.4%,平均剂量12.2 mg/天,中位疗程5天;脑室内氨基糖苷类使用率47.5%,庆大霉素/妥布霉素平均剂量6.7 mg/天,中位疗程6天。
  • 总体死亡率18.1%;脑脊液培养转阴率88.4%,培养持续阳性或复发率9.5%。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:作者指出需前瞻性研究来确定最佳患者人群以及该给药途径的疗效与安全性。

对床旁实践的改变

  • 作者认为脑室内抗菌药物可带来高脑脊液培养转阴率(88.4%),当前使用疗程通常不足一周。
  • 作者认为需前瞻性研究确定最佳患者人群及该给药途径的疗效与安全性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Central nervous system (CNS) infections are particularly prevalent in the adult neurocritical care patient population and are associated with significant morbidity and mortality. Factors relevant to the nature of CNS infections pose significant challenges to clinicians treating afflicted patients. Intraventricular (IVT) administration of antibiotics may offer several benefits over systemic therapy; however, the outcomes and current practices of such treatments are poorly described in the literature.

OBJECTIVE: To describe current practices and outcomes of patients receiving intraventricular antibiotic treatment for CNS infections in neurological intensive care units of academic medical centers nationwide.

METHODS: A retrospective cohort study was conducted on patients admitted to intensive care units who received IVT antibiotic treatment at participating centers in the USA between January 01, 2003, and December 31, 2013. Clinical and laboratory parameters, microbiology, surgical and antimicrobial management, and treatment outcomes were collected and described.

RESULTS: Of the 105 patients included, all received systemic antimicrobial therapy along with at least one dose of IVT antimicrobial agents. Intraventricular vancomycin was used in 52.4% of patients. The average dose was 12.2 mg/day for a median duration of 5 days. Intraventricular aminoglycosides were used in 47.5% of the patients, either alone or in combination with IVT vancomycin. The average dose of gentamicin/tobramycin was 6.7 mg/day with a median duration of 6 days. Overall mortality was 18.1%. Cerebrospinal fluid (CSF) culture sterilization occurred in 88.4% of the patients with a rate of recurrence or persistence of positive cultures of 9.5%.

CONCLUSION: Intraventricular antimicrobial agents resulted in a high CSF sterilization rate. Contemporary use of this route typically results in a treatment duration of less than a week. Prospective studies are needed to establish the optimal patient population, as well as the efficacy and safety of this route of administration.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Lewin JJ, Cook AM, Gonzales C, et al. Current Practices of Intraventricular Antibiotic Therapy in the Treatment of Meningitis and Ventriculitis: Results from a Multicenter Retrospective Cohort Study. Neurocrit Care. 2019. PMID: 30446934. doi:10.1007/s12028-018-0647-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。